

With the support of Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA

Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse, Belgium

Janssen-Cilag B.V.
Graaf Engelbertlaan 75
4837 DS Breda
Nederland

OPTIMISING OUTCOMES FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: AN EXPERT-LED WORKSHOP

Program and Faculty Information

Friday 24 November 2017

Amsterdam Marriott Hotel, Amsterdam

Program starts at 08:30

Program ends at 15:45

Scientific Committee

Paolo Ghia, Italy

 Hematology
Medical
Education

Janssen  Oncology

PHARMACEUTICAL COMPANIES OF Johnson & Johnson

Dear Colleague

Welcome to this expert-led meeting focusing on the practical management of patients with chronic lymphocytic leukemia (CLL) in the era of novel agents.

The workshops will provide you with the opportunity to participate in a series of interactive discussions with our experienced faculty and other international hematologists on the key considerations we have when managing our CLL patients to ensure optimised outcomes.

We hope you enjoy what promises to be a lively and stimulating meeting.



Paolo Ghia
Scientific Committee

Learning objectives

After attending this educational program, you should be able to:

- Discuss practical management of patients with CLL in the era of novel therapies
- Describe how to improve patient outcomes through optimal patient management.

This medical educational program is designed for hematologists with a special interest in treating patients with CLL.

Program overview

- 08:30–09:15 Opening plenary
- 09:15–10:30 Parallel workshop session
- 10:30–10:45 *Coffee*
- 10:45–12:00 Parallel workshop session
- 12:00–12:45 *Lunch*
- 12:45–14:00 Parallel workshop session
- 14:00–14:15 *Coffee*
- 14:15–15:30 Parallel workshop session
- 15:30–15:45 Closing plenary session

Parallel scientific workshop topics

Topic 1

Optimising outcomes of patients treated with BTK inhibitors

Topic 3

Reviewing the experience with Bcl-2 inhibitors in CLL

Topic 2

Considering chemoimmunotherapy in the era of novel agents

Topic 4

Managing your patients with PI3-kinase inhibitors

Faculty

- Florence Cymbalista, France
- John Gribben, UK
- Peter Hillmen, UK
- Carol Moreno, Spain
- Stephan Stilgenbauer, Germany

SCIENTIFIC COMMITTEE



Paolo Ghia

Paolo Ghia is Associate Professor in Internal Medicine at the Università Vita-Salute San Raffaele and Deputy Chair of the Division of Molecular Oncology at the San Raffaele Scientific Institute in Milan, Italy. He is Head of the Laboratory of B-cell Neoplasia and Director of the Strategic Research Program on CLL, where he is National Coordinator/Principal Investigator of Phase 1-3 clinical trials in CLL. Professor Ghia's main research interest is the study of the molecular and cellular mechanisms acting in the natural history of CLL, including monoclonal B-cell lymphocytosis (MBL). He has published over 200 manuscripts on these topics in peer-reviewed journals.

FACULTY



Florence Cymbalista

Florence Cymbalista is Professor of Hematology and Head of the Department of Biological Hematology at the University Hospital Avicenne in Bobigny, France. Her research interests include chronic lymphoproliferative disorders, the development of new biological tools for the prognosis and follow-up of CLL patients, and B-cell receptor signalling and its impact on CLL heterogeneity.

FACULTY



John Gribben

John Gribben is Hamilton Fairley Professor of Medical Oncology at Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary University of London, UK. After doctoral studies at University College London, where he was the recipient of a Wellcome Trust Fellowship Award, he received a Fogarty International Fellowship to continue postdoctoral training at the Dana-Farber Cancer Institute, Harvard Medical School, in Boston, USA. In 1992, Professor Gribben was appointed to the faculty at Harvard Medical School, where he remained as Associate Professor of

Medicine and attending physician until returning to London in 2004. He is an internationally recognized translational cancer researcher and the author of more than 380 manuscripts and 60 book chapters. Professor Gribben's primary research interests include the management of lymphoma and CLL, immunotherapy of cancer (including stem-cell transplantation), the identification of tumour antigens, and eradication of minimal residual disease. He was recently awarded the prestigious Binet-Rai Medal for his outstanding contribution to CLL research and acknowledged for his work on the impact of CLL on the host immune system and delineating the mechanisms for this, and for his pioneering work on stem cell transplantation in CLL.

FACULTY



Peter Hillmen

Peter Hillmen has been Professor of Experimental Haematology at the University of Leeds, UK, since 2013 and an Honorary Consultant Haematologist at St James's University Hospital, Leeds. Professor Hillmen qualified from Leeds Medical School in 1985 and completed his general medical training in Leeds. In 1989, he started general hematology training at Hammersmith Hospital in London. In 1993, he was awarded a PhD by the University of London for research into the biochemical and molecular defect in paroxysmal nocturnal hemoglobinuria (PNH). Professor Hillmen

was appointed as a Consultant Haematologist at the Mid-Yorkshire Trust and Leeds General Infirmary in 1996 before moving to Leeds Teaching Hospitals NHS Trust in 2004. Professor Hillmen has research interests in both PNH and CLL. He chairs the NCRI CLL sub-group in the UK responsible for the development of UK CLL clinical trials. He was recently awarded the prestigious Binet-Rai Medal for his outstanding contribution to CLL research.

FACULTY



Carol Moreno

Carol Moreno is a Senior Staff Member at the Department of Hematology of the Hospital de Sant Pau i Santa Creu, Autonomous University of Barcelona, Spain, where she combines clinical work in the Department of Hematology with research activity in the Oncology/Hematology and Transplantation Group of the Biomedical Research Institute of Sant Pau (IIB-Sant Pau). She is coordinator of the CLL Program and Principal Investigator of numerous clinical trials. Dr Moreno is a board member of the European Research Initiative on CLL (ERIC), where she is involved in different clinical and translational projects. She is also a board member of the Spanish Group on Hematological Malignancies in the Elderly, and a member of the Scientific Committee of the José Carreras Research Institute and the European Hematology Association (EHA) Scientific Programme Committee. She has been an EHA reviewer associate since 2014. She has published over 40 papers in peer-reviewed journals.

FACULTY



Stephan Stilgenbauer

Stephan Stilgenbauer is Associate Professor and Deputy Chair in the Department of Internal Medicine III (hematology, oncology, rheumatology, and infectious diseases) at Ulm University, Germany. He undertook his medical training at Heidelberg Medical School, Germany, and was trained in internal medicine and hematology-oncology at the Universities of Heidelberg and Ulm. He then completed a postdoctoral fellowship at the German Cancer Research Center (DKFZ) in Heidelberg. His research focus is on molecular pathogenesis and translation into novel treatment strategies in hematological malignancies. Dr Stilgenbauer has authored and co-authored numerous original articles, reviews, and book chapters in journals such as the *New England Journal of Medicine*, *The Lancet*, *Nature Medicine*, *Proceedings of the National Academy of Sciences of the USA*, *Journal of Clinical Oncology*, *Blood*, *Leukemia*, and *Haematologica*.

